Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-06-2009 | Original Paper

Inhibitor of growth 4 induces apoptosis in human lung adenocarcinoma cell line A549 via Bcl-2 family proteins and mitochondria apoptosis pathway

Authors: Xiaomei Li, Qingyuan Zhang, Limin Cai, Yanhua Wang, Qian Wang, Xiaoyi Huang, Songbin Fu, Jing Bai, Jinglei Liu, Guangmei Zhang, Jiping Qi

Published in: Journal of Cancer Research and Clinical Oncology | Issue 6/2009

Abstract

Objective

Inhibitor of growth 4 (ING4) is considered to be a tumor suppressor implicated in several human malignancies by tumor growth inhibition and apoptosis enhancement. In present study, the effects of ING4 on apoptosis and its mechanisms were investigated through the transduction of ING4 cDNA into lung adenocarcinoma cell line A549.

Methods

The effects of ING4 on A549 apoptosis were observed by FCM analysis, TUNEL assay, and electron microscopy. Simultaneously, the effects of ING4 on the expression of several apoptosis-related proteins in cell line A549 were evaluated by Western blot analysis.

Results

Both Annexin-V FITC analysis by FCM and TUNEL assay revealed more apoptotic cells in A549 cells with exogenous ING4 gene. For electron microscopy, A549 cells with exogenous ING4 gene showed typical morphological changes of apoptosis. The deregulation of Bcl-2 family proteins (Bcl-2, Bcl-xl, Bax, Bak, Bid) and the major apoptotic executioners of mitochondria pathway (Cyt-c, caspase3, PARP) were also observed.

Conclusion

Our findings suggest that exogenous ING4 can enhance A549 apoptosis via regulating the expression of Bcl-2 family proteins and the activation of mitochondrial apoptotic pathway.

Adams JM, Cory S (2001) Life-or-death decisions by the Bcl-2 protein family. Trends Biochem Sci 26:61–66. doi:10.1016/S0968-0004(00)01740-0 PubMedCrossRef

Cheng EH, Wei MC, Weiler S et al (2001) BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol Cell 8:705–711. doi:10.1016/S1097-2765(01)00320-3 PubMedCrossRef

Desagher S, Osen-Sand A, Nichols A et al (1999) Bid-induced conformational change of bax is responsible for mitochondrial cytochrome c release during apoptosis. J Cell Biol 144:891–901. doi:10.1083/jcb.144.5.891 PubMedCrossRef

Garkavtsev I, Kozin SV, Chernova O et al (2004) The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis. Nature 428:328–332. doi:10.1038/nature02329 PubMedCrossRef

Green DR, Evan GI (2002) A matter of life and death. Cancer Cell 1:19–30. doi:10.1016/S1535-6108(02)00024-7 PubMedCrossRef

Gunduz M, Nagatsuka H, Demircan K et al (2005) Frequent deletion and down-regulation of ING4, a candidate tumor suppressor gene at 12p13, in head and neck squamous cell carcinomas. Gene 356:109–117. doi:10.1016/j.gene.2005.02.014 PubMedCrossRef

Hwang JH, Lim SC, Kim YC et al (2001) Apoptosis and bcl-2 expression as predictors of survival in radiation-treated non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 50:13–18. doi:10.1016/S0360-3016(00)01558-3 PubMed

Joseph B, Ekedahl J, Sirzen F et al (1999) Differences in expression of pro-caspases insmall cell and non-small cell lung carcinoma. Biochem Biophys Res Commun 262:381–387. doi:10.1006/bbrc.1999.1191 PubMedCrossRef

Karczmarek-Borowska B, Filip A, Wojcierowski J et al (2006) Estimation of prognostic value of Bcl-XL gene expression in non-small cell lung cancer. Lung Cancer 51:61–69. doi:10.1016/j.lungcan.2005.08.010 PubMedCrossRef

Kim S, Chin K, Gray JW et al (2004) A screen for genes that suppress loss of contact inhibition: identification of ING4 as a candidate tumor suppressor gene in human cancer. Proc Natl Acad Sci USA 101:16251–16256. doi:10.1073/pnas.0407158101 PubMedCrossRef

Kuwana T, Mackey MR, Perkins G et al (2002) Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane. Cell 111:331–342. doi:10.1016/S0092-8674(02)01036-X PubMedCrossRef

Li X, Cai L, Liang M et al (2008) ING4 induces cell growth inhibition in human lung adenocarcinoma A549 cells by means of Wnt-1/beta-catenin signaling pathway. Anat Rec 291:593–600. doi:10.1002/ar.20685 CrossRef

Shiseki M, Nagashima M, Pedeux RM et al (2003) p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity. Cancer Res 63:2373–2378PubMed

Yu X, Zhang HF, Wang JZ et al (2007) Ad-ING4 inhibits K562 cell growth. Zhonghua Xue Ye Xue Za Zhi 28:396–400PubMed

Zhang X, Xu LS, Wang ZQ et al (2004) ING4 induces G2/M cell cycle arrest and enhances the chemosensitivity to DNA-damage agents in HepG2 cells. FEBS Lett 570:7–12. doi:10.1016/j.febslet.2004.06.010 PubMedCrossRef

Zhao Y, Li S, Childs EE et al (2001) Activation of pro-death Bcl-2 family proteins and mitochondria apoptosis pathway in tumor necrosis factor-alpha-induced liver injury. J Biol Chem 276:27432–27440. doi:10.1074/jbc.M102465200 PubMedCrossRef

Title: Inhibitor of growth 4 induces apoptosis in human lung adenocarcinoma cell line A549 via Bcl-2 family proteins and mitochondria apoptosis pathway
Authors: Xiaomei Li
Qingyuan Zhang
Limin Cai
Yanhua Wang
Qian Wang
Xiaoyi Huang
Songbin Fu
Jing Bai
Jinglei Liu
Guangmei Zhang
Jiping Qi
Publication date: 01-06-2009
Publisher: Springer-Verlag
Published in: Journal of Cancer Research and Clinical Oncology / Issue 6/2009
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-008-0519-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2009

Upregulation of the cycline kinase subunit CKS2 increases cell proliferation rate in gastric cancer

Salvage therapy with topotecan in heavily pretreated ovarian cancer patients

Preoperative cervical lymph node size evaluation in patients with malignant head/neck tumors: comparison between ultrasound and computer tomography

Incidence of joint symptoms and bone fractures in Japanese postmenopausal breast cancer patients treated with adjuvant anastrozole

Current place of high-dose irinotecan chemotherapy in patients with metastatic colorectal cancer

Expression of stathmin/op18 as a significant prognostic factor for cervical carcinoma patients

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials